Owen Mumford unveiled a new addition to its range of automatic injection devices at the CPHI event in Paris.
Presented for the first time, the Autoject®Micro is a new disposable auto-injector that features a patented drive mechanism technology that enables auto-injection in a more discreet package.
“Autoject® Micro has been developed to make it easier for patients and healthcare professionals to deliver single dose injectable treatments while also addressing cold store and logistics costs with its smaller form factor,” said George I’ons, Business Development Manager, Owen Mumford. “Its intuitive design and safety features have been created to address key patient concerns such as needlestick anxiety and adherence, while providing advanced drug delivery capabilities. It can be supplied fully assembled with a prefilled syringe or in two parts ready for final assembly.”
The Autoject® Micro introduces a number of innovative features including a unique lockout mechanism that lets patients use the device in the way that is most intuitive to them; and being a small device, it takes up less space meaning you can fit more on a palette and with this, reduce storage and shipping costs.
The Autoject® Micro can be activated either by the push of a button or on contact. It also conceals the needle before and after use to reduce needle injection anxiety and prevent sharps injury. The Autoject® Micro provides audible and visual feedback with an activation button appearing when the device is unlocked and ready to use. A protective cap and locking mechanism prevents accidental activation and a large viewing window provides easy viewing of the syringe. The ergonomic oval shape of the Autoject® Micro features a large grip detail on the cap designed to make treatment easier to administer.
With the introduction of the Autoject® Micro, Owen Mumford expands its range of automatic injection devices for the self-administration of parenteral drugs. These include single dose and multi dose reusable and disposable auto-injectors and pen injectors (e.g. insulin pens), which are suitable for a wide range of primary containers, including prefilled glass and plastic syringes and prefilled cartridges. Designed to meet the individual needs of pharmaceutical and biotech partners and those of varying user groups, these parenteral drug delivery systems facilitate ease of use and improve safety and patient compliance.
